ONS 2014: Highlights in Multiple Myeloma
Release Date: May 28, 2014
Expiration Date: May 28, 2015
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Experienced oncology nurse leaders provide key discussions on research, treatment adherence, survivorship, and side-effect management you need to know in caring for your patients with multiple myeloma.
Each segment will provide you with brief highlights from select presentations focusing on multiple myeloma which occurred at the Oncology Nurses Society 39th Annual Congress.
This activity is designed for nurse practitioners, nurses, and other health care professionals who have an interest in enhancing their clinical skills in treating patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Provide clinical and evidence-based content that relates the importance of patient adherence, specifically with ongoing treatment
- Summarize findings in supportive care and the management of multiple myeloma patients as presented at the ONS Annual Meeting
ONS 2014: Highlights in Multiple Myeloma – Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN® (Moderator)
Importance of “Survivorship” and Care of the Caregiver – Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
Importance of Patient Adherence with Ongoing Treatment – Page Bertolotti, RN, BSN, OCN
Management of Side Effects from Novel Agents – Elizabeth Finley-Oliver, RN, OCN
What We Currently Know about Smoldering Myeloma – Joseph D. Tariman, PhD
Instructions for Participation and Credit
This activity is eligible for credit through May 28, 2015. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®
Multiple Myeloma Program
Cleveland Clinic Foundation
Beth Faiman received her master of science degree in nursing and certification as an adult nurse practitioner at Kent State University, Ohio. She holds an advanced oncology nurse certification through ANCC and is a pre-doctoral research fellow at the Frances Payne Bolton School of Nursing at Case Western Reserve in Cleveland, Ohio. Ms. Faiman is currently employed as an adult nurse practitioner at the Cleveland Clinic.
A member of several professional associations including the Oncology Nursing Society, Cleveland Chapter Oncology Nursing Society, Ohio Academy of Advanced Practice Nurses, and American Association of Nurse Practitioners, Ms. Faiman is also co-chair of the Nurses Excellence Awards Committee for the Cleveland Clinic, and is current chair of the Advanced Practice Nurse Council for the Cleveland Clinic. In addition, she is an appointed delegate on the Nursing Leadership Board for the International Myeloma Foundation. Ms. Faiman is the editor-in-chief of The Oncology Nurse. She has co-authored several articles relating to the treatment of refractory and relapsing myeloma treatment and has been published in Mayo Clinic Proceedings, Clinical Journal of Oncology Nursing, and has authored several chapters related to diagnosis and management of multiple myeloma. Ms. Faiman is an active presenter and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications.
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
Clinical Assistant Professor of Medicine and Nursing
University of Arizona
Hematology/Oncology Nurse Practitioner
Arizona Cancer Center
Sandra Kurtin is a hematology/oncology nurse practitioner at the Arizona Cancer Center, and clinical assistant professor of medicine and nursing at the University of Arizona in Tucson, Arizona. Ms. Kurtin has oncology nursing experience in a variety of roles, most recently as an oncology nurse practitioner in a comprehensive cancer center. Ms. Kurtin received her master of science in nursing degree (with a focus on oncology), and post-masters nurse practitioner certification in adults and geriatrics from the University of Arizona. She is certified with the American Nurses Association and Oncology Nursing Society.
Ms. Kurtin is a member of the American Academy of Nurse Practitioners, Oncology Nursing Society, and Nightingale Honors Society. She has presented numerous regional, national, and international lectures on oncology, chemotherapy administration, and clinical research. Ms. Kurtin is on the editorial board of The Oncology Nurse, Oncology: Nurse Edition, and is associate editor of Journal of the Advanced Practitioner in Oncology. She serves as co-chair of the International Nursing Advisory Board: The MDS Foundation, and is a member of the International Myeloma Foundation Nursing Leadership Board. She has published several articles in peer-reviewed journals including The New England Journal of Medicine, Cancer Nursing, Blood, Leukemia Research, and Clinical Journal of Oncology Nursing.
Page Bertolotti, RN, BSN, OCN
Clinical Practice Nurse
Multiple Myeloma and Amyloidosis Program
Samuel Oschin Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California
Page Bertolotti received her associate of science in nursing degree from the Moorpark Community College Nursing School in Moorpark, California. Her most memorable patient died of lymphoma and this experience sealed her passion for hematology oncology, so she obtained her oncology nurse certification through Oncology Nursing Certification Corporation (ONCC) and her bachelor of science in nursing degree from the University of Phoenix. Ms. Bertolotti is a clinical practice nurse with the multiple myeloma and amyloidosis program at the Samuel Oschin Cancer Center at Cedars-Sinai Medical Center in Los Angeles.
Ms. Bertolotti is an appointed delegate to the Nurse Leadership Board of the International Myeloma Foundation. She has served as president of her local ONS chapter and co-chair of the Clinical Practice and Education Taskforce of the Ambulatory Clinical Practice Council at Cedars-Sinai Medical Center. She has publications in the Clinical Journal of Oncology Nursing on “Managing the side effects of novel agents for multiple myeloma,” as well as a “Survivorship Care Plan for Multiple Myeloma.” She has lectured extensively on the topics of multiple myeloma as well as myelodysplastic syndrome.
Elizabeth Finley-Oliver, RN, OCN
H. Lee Moffitt Cancer Center and Research Institute
Elizabeth Finley-Oliver is a specialized oncology nurse with more than five years of multiple myeloma and other plasma cell dyscrasias patient management experience, including research coordination, clinic staff training, and regional speaking. Her duties at H. Lee Moffitt Cancer Center and Research Institute include implementing and managing all REMS requirements for various myeloma therapies and assisting with research protocols, ensuring compliance and patient/staff adherence with REMS requirements.
Through partnership with myeloma specialists and numerous experiences with hundreds of myeloma patients, Ms. Finley-Oliver has been able to become a ‘nursing expert’ within the myeloma specialty field and recognizes the need to continually learn and grow in clinical understanding of plasma cell dyscrasias. She has lectured on these topics to audiences of patients, nurses, and physicians throughout the Southern Region.
Joseph D. Tariman, PhD
College of Science and Health & College of Nursing
De Paul University
Dr. Joseph Tariman received his PhD at University of Washington where he received his research fellowship funded by National Institute of Health and the Achievement Rewards for College Scientists Foundation. He obtained his BSN from University of the Visayas, master of arts in nursing at Cebu Doctors’ University, and a post-master’s certificate in adult health at University of Miami, Coral Gables, Florida. Dr. Tariman worked as an advanced practice nurse at Northwestern University Myeloma Program in Chicago, primarily responsible as sub-principal investigator for all phase 1 and 2 clinical therapeutic trials for myeloma. He has been an advanced practitioner in oncology since 2001 and is currently an oncology nurse consultant. In addition, he is an assistant professor, College of Science and Health & College of Nursing at De Paul University in Chicago.
Dr. Tariman is one of the founding members of the International Myeloma Foundation’s Nurse Leadership Board and Chair of the IMF NLB research committee. He is currently serving a three-year term as a member of the ONS Foundation Board of Trustees. Dr. Tariman is a member of the editorial review boards of Clinical Journal of Oncology Nursing and Oncology Nursing Forum. He has served as contributing editor for ONS Connect and as a column writer for Advance for Nurse Practitioners. In addition, he edited a groundbreaking nursing book on multiple myeloma published by ONS Publishing and will be co-editing the 2nd edition of the Myeloma Book for Nurses entitled, A Treatment-focused and Evidenced-based Approach to the Care of Patients with Myeloma, which is scheduled for press release in May 2015. He has authored more than 75 published articles, abstracts, monographs, and five book chapters on various topics including multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 14-011-348
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Beth Faiman has received honoraria related to speakers’ bureau activities and as a consultant from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx.
Sandra Kurtin has received honoraria as a consultant from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx.
Page Bertolotti has received honoraria related to formal advisory activities from Celgene Corporation, as well as speakers’ bureau activities from Celgene, Millennium: The Takeda Oncology Company, and Onyx.
Elizabeth Finley-Oliver has received honoraria related to speakers’ bureau activities from Celgene Corporation and Onyx.
Dr. Joseph Tariman has received honoraria related to speakers’ bureau activities from Millennium: The Takeda Oncology Company and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Ms. Faiman, Kurtin, and Bertolotti have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Ms. Faiman, Kurtin, and Bertolotti have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Ms. Finley-Oliver and Dr. Joseph Tariman have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Ms. Finley-Oliver and Dr. Joseph Tariman have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.